SecurityWFC.PRW / Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W (94988U714)
IndustryNational Commercial Banks
Institutional Owners7
Institutional Shares186,291 - 0.00%
Common Shares Outstanding4,816,137,157 shares (as of 2018-06-30)
Institutional Value$ 4,701,000 USD
Related 33738MAB7 / 1st Un Natl Bk Charlotte Mtnbe Fr 6.5% 12/01/2028
33738MAA9 / 1st Un Natl Bk Charlotte Mtnbe Put 6.18% 02/22/2036
33738MAG6 / 1st Un Natl Bk Charlotte Mtnbe Put 6.919% 12/15/2036
33738KAA3 / 1st Un Natl Bk Jacksonvi Mtnbe Fr 6.18% 02/15/2036
337358BD6 / First Union Corp 6.55% Sub Debs 10/15/35
337358BA2 / First Union Corp 7.5% Sub Debs 4/15/35
66938FJU9 / Norwest Corp Medterm Notes Bk En Fr 6.75% 12/15/27
669380AW7 / Norwest Corp Sub Debentures 6.65% 10/15/23
8447HEAA4 / Southtrust Bk Atlanta Sub Mtn Put 7.74% 05/15/2025
8447HBAC6 / Southtrust Bk Birmgham Sub Mtn Fr 6.565% 12/15/27
8447HBAE2 / Southtrust Bk Birmgham Sub Mtn Put 6.125% 01/09/2028
8447HBAA0 / Southtrust Bk Birmgham Sub Mtn Put 7.69% 05/15/2025
844730AG6 / Southtrust Corp Subordinated Notes 5.8% 06/15/14
92976GAE1 / Wachovia Bk Natl Assn Mtn Sub Call 5.6% 03/15/16
92976GAB7 / Wachovia Bk Natl Assn Mtn Sub Fr 4.8% 11/01/2014
92976GAD3 / Wachovia Bk Natl Assn Mtn Sub Fr 4.875% 02/01/2015
92976GAA9 / Wachovia Bk Natl Assn Mtn Sub Fr 5% 08/15/2015
92976GAG6 / Wachovia Bk Natl Assn Mtn Sub Fr 5.85% 02/01/2037
92976GAH4 / Wachovia Bk Natl Assn Mtn Sub Fr 6% 11/15/2017
92976GAJ0 / Wachovia Bk Natl Assn Mtn Sub Fr 6.6% 01/15/2038
92978AAA0 / Wachovia Capital Trust Iii 5.80
929903AE2 / Wachovia Corp 4.875% Subordinated Notes 02/15/14
929903AJ1 / Wachovia Corp 5.250% Subordinated Notes 08/01/14
929903AM4 / Wachovia Corp 5.5% Notes 8/1/2035
92976WBJ4 / Wachovia Corp. 5.5% Senior Notes 5/1/13
929903CH3 / Wachovia Corp 5.625% Notes 10/15/2016
929903DT6 / Wachovia Corp 5.75% Notes 6/15/17
92976WBH8 / Wachovia Corp 5.75% Senior Notes 2/1/18
92976WBA3 / Wachovia Corp 5.7% Notes 8/1/2013
929771AE3 / Wachovia Corp 6.605% Notes 10/1/2025
949746NX5 / Wells Fargo 5.625% Senior Notes 12/11/17
94980VAA6 / Wells Fargo Bank Na 4.75% 02/09/15
94978SAA7 / Wells Fargo Cap X Cap Sec 5.95% 12/01/86
WFCNP / Wells Fargo & Co.
WFC / Wells Fargo & Co.
94974BFA3 / Wells Fargo & Co. 1.25% 02/13/15
94974BFG0 / Wells Fargo & Co. 1.50% 01/16/18
94974BFE5 / Wells Fargo & Co. 1.50% 07/01/15
94974BFD7 / Wells Fargo & Co. 2.10% 05/08/17
94974BFJ4 / Wells Fargo & Co. 3.45% 02/13/23
94974BFC9 / Wells Fargo Co 3.50% Senior Notes 03/08/22
949746FS5 / Wells Fargo & Co 4.625% Subordinated Notes 4/15/14
949746FJ5 / Wells Fargo & Co 4.950% Subordinated Notes 10/16/13
949746CR0 / Wells Fargo & Co 5.000% Subordinated Notes 11/15/14
WFC.PRO / Wells Fargo & Co., 5.125% Dep Shares Non-Cumul Perp Preferred Stock Series O
949746JE2 / Wells Fargo & Co. 5.125% Notes 9/15/16
WFC.PRN / Wells Fargo & Co., 5.20% Dep Shares Non-cumul Perp Cl A Preferred Stock Series N
WFC.PRP / Wells Fargo & Co., 5.25% Dep Shares Non-Cumul Perp Preferred Stock Series P
949746JM4 / Wells Fargo & Co. 5.375% Notes 2/7/35
WFC.PRX / Wells Fargo & Co., 5.50% Dep Shares Non-Cumul Class A Preferred Stock Series X
WFC.PRQ / Wells Fargo & Co., 5.85% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser Q
WFC.PRT / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series T
WFC.PRV / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series V
WFC.PRR / Wells Fargo & Co., 6.625% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser R
WFC.PRL / Wells Fargo & Co., 7.50% Non-Cumul Perp Conv Cl A Preferred Stock, Series L
WFC.PRJ / Wells Fargo & Co., 8.00% Dep Shares Non-cumul Perp Cl A Preferred Stock Series J
94986RTK7 / Wells Fargo & Co. Bond
94974BFN5 / Wells Fargo & Co. Bond
94986RPJ4 / Wells Fargo & Co. Bond
WFC.PRY / Wells Fargo & Company
94974BEZ9 / Wells Fargo & Company 2.625% 12/15/16
94974BEU0 / Wells Fargo & Company 3.625% Senior Notes 04/15/15
94974BEV8 / Wells Fargo & Company 4.60% Notes 04/01/21
WFC.PRJCL / Wells Fargo & Company Depositary Shares (Each representing a 1/40th interest in a share of 8.00% Non
94974BET3 / Wells Fargo Co Mtn Be Senior Notes 3.75% 10/01/14
94986RFK2 / Wells Fargo & Co. SE
WFC.WS / Wells Fargo & Co. (Warrant)

Institutional Stock Ownership and Shareholders

WFC.PRW / Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W Institutional Ownership

Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W (NYSE:WFC.PRW) has 7 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 186,291 shares. Largest shareholders include Fulton Breakefield Broenniman LLC, Selway Asset Management, Cim Investment Mangement Inc, D L Carlson Investment Group Inc, Apriem Advisors, Old Second National Bank Of Aurora, and Pnc Financial Services Group, Inc..
Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W (NYSE:WFC.PRW) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-02 13F-HR Fulton Breakefield Broenniman LLC 65,436 66,416 1.50 1,649 1,675 1.58
2018-07-25 13F-HR OLD SECOND NATIONAL BANK OF AURORA 1,000 1,000 0.00 25 25 0.00
2018-08-14 13F-HR Apriem Advisors 0 4,400 0 111
2018-07-24 13F-HR Selway Asset Management 48,925 45,075 -7.87 1,233 1,137 -7.79
2018-08-10 13F-HR D L CARLSON INVESTMENT GROUP INC 25,900 28,600 10.42 653 721 10.41
2018-08-07 13F-HR CIM INVESTMENT MANGEMENT INC 40,000 40,000 0.00 1,005 1,012 0.70

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Amazon Roundup: Ad Market Share, Store Expansion, Prime, More

7h zacks
Amazon (AMZN - Free Report) may be rapidly gaining digital advertising market share, but it also has a comprehensive physical store expansion up its sleeve. So despite the valuation, analysts continue to raise their price targets- (12-0)

Dividend ETFs: Don't Bank On Stable Dividends

12h seekingalpha
Huge dividend cuts during 2008-2009 combined with unstable dividend payments are causes for concern for dividend-seeking investors. (68-2)

Top Analyst Reports for Netflix, EOG Resources & Simon Property Group

13h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), EOG Resources (EOG) and Simon Property Group (SPG). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (38-1)

Bank Stock Roundup: Economic Growth Inspires Optimism, WFC & BofA in Focus

15h zacks
Over the last five trading days, major banks’ rally continued on expectation of interest rate hike this month. The rate hike will translate into top-line expansion for banks, leading to improved results in the quarters ahead. Further, given the growth in economy, low unemployment rate and healthy consumer sentiment, the demand for loans and other related products of banks are expected to rise. However, imposition of tariffs on $200 billion worth of Chinese goods next week could escalate trade war tensions, impacting consumers and increasing inflation. (59-0)

Top Analyst Upgrades and Downgrades: AMD, Alcoa, AT&T, Darden, Micron, New Age Beverages, Nike, Novavax, Pier 1, Under Armour and More

17h 247wallst
Stocks were indicated marginally higher on Friday, but this as after the Dow Jones industrials and S&P 500 hit all-time high closes on Thursday. International markets were also higher on Friday, but many international and emerging markets are still very far away from their all-time highs. As many investors have seen lower upside from buying on market pullbacks than in prior years, they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches. (60-1)

Stocks making the biggest move premarket: MU, MCD, T, TXN, WMT & more

17h cnbc
Micron Technology– Micron reported adjusted quarterly profit of $3.53 per share, beating the consensus estimate of $3.34 a share. The chipmaker's revenue also topped forecasts, however the stock erased an initial gain after company executives said U.S. tariffs on China goods would impact its financial results for as much as one year. (26-0)

The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

17h zacks
Chicago, IL – September 21, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Wells Fargo (WFC - Free Report) , Schlumberger (SLB - Free Report) , Biogen (BIIB - Free Report) , American Express (AXP - Free Report) and Illinois Tool Works (ITW - Free Report) . (12-0)

Wells Fargo to Trim Headcount by 5-10% Over Three Years

18h zacks
Wells Fargo & Company’s (WFC - Free Report) CEO Tim Sloan, in a bi-monthly meeting held on Thursday, said that the company plans to reduce its workforce by 5-10% in the next three years, as it seeks to transform itself into a more efficient and customer-oriented firm. (4-0)

Goldman Sachs Faces Lawsuit by 2 Leading Brokerage Firms

18h zacks
A lawsuit is filed against The Goldman Sachs Group (GS - Free Report) by two brokerage firms — The Charles Schwab Corporation (SCHW - Free Report) and TD Ameritrade Holding Corporation (AMTD - Free Report) — over a 17-year old stock-sharing agreement, per an article by Reuters. (9-0)

Wells Fargo is going backwards with thousands of job cuts as JP Morgan and other banks boom

19h cnbc
Wells Fargo Chief Executive Officer Tim Sloan is cutting jobs with the hope that he can save his own. (4-0)

CUSIP: 94988U714